| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre … R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ... The lancet oncology 15 (10), 1100-1108, 2014 | 1020 | 2014 |
| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The Lancet Oncology 18 (10), 1373-1385, 2017 | 954 | 2017 |
| Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications E Dal Canto, A Ceriello, L Rydén, M Ferrini, TB Hansen, O Schnell, ... European journal of preventive cardiology 26 (2_suppl), 25-32, 2019 | 571 | 2019 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study H Gacaferi, GS Collaborative, COVIDSurg Collaborative Anaesthesia 76 (6), 2021 | 538* | 2021 |
| Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a … U Herrlinger, T Tzaridis, F Mack, JP Steinbach, U Schlegel, M Sabel, ... The lancet 393 (10172), 678-688, 2019 | 477 | 2019 |
| Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man AJ Beer, R Haubner, M Sarbia, M Goebel, S Luderschmidt, AL Grosu, ... Clinical Cancer Research 12 (13), 3942-3949, 2006 | 439 | 2006 |
| MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial M Weller, G Tabatabai, B Kästner, J Felsberg, JP Steinbach, A Wick, ... Clinical cancer research 21 (9), 2057-2064, 2015 | 364 | 2015 |
| Mapping microglia states in the human brain through the integration of high-dimensional techniques R Sankowski, C Böttcher, T Masuda, L Geirsdottir, Sagar, E Sindram, ... Nature neuroscience 22 (12), 2098-2110, 2019 | 341 | 2019 |
| The global epidemics of diabetes in the 21st century: Current situation and perspectives E Standl, K Khunti, TB Hansen, O Schnell European journal of preventive cardiology 26 (2_suppl), 7-14, 2019 | 320 | 2019 |
| Predictive impact of MGMT promoter methylation in glioblastoma of the elderly G Reifenberger, B Hentschel, J Felsberg, G Schackert, M Simon, ... International journal of cancer 131 (6), 1342-1350, 2012 | 310 | 2012 |
| Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries G De Backer, P Jankowski, K Kotseva, E Mirrakhimov, Ž Reiner, L Ryden, ... Atherosclerosis 285, 135-146, 2019 | 306 | 2019 |
| Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma D Henrik Heiland, VM Ravi, SP Behringer, JH Frenking, J Wurm, ... Nature communications 10 (1), 2541, 2019 | 286 | 2019 |
| A vaccine targeting mutant IDH1 in newly diagnosed glioma M Platten, L Bunse, A Wick, T Bunse, L Le Cornet, I Harting, F Sahm, ... Nature 592 (7854), 463-468, 2021 | 281 | 2021 |
| Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography O Schnell, B Krebs, J Carlsen, I Miederer, C Goetz, RH Goldbrunner, ... Neuro-oncology 11 (6), 861-870, 2009 | 250 | 2009 |
| Postprandial hyperglycemia and glycemic variability: should we care? E Standl, O Schnell, A Ceriello Diabetes care 34 (Supplement_2), S120-S127, 2011 | 237 | 2011 |
| Expression of Integrin αvβ3 in Gliomas Correlates with Tumor Grade and Is not Restricted to Tumor Vasculature O Schnell, B Krebs, E Wagner, A Romagna, AJ Beer, SJ Grau, N Thon, ... Brain pathology 18 (3), 378-386, 2008 | 220 | 2008 |
| Molecular markers in low-grade gliomas: predictive or prognostic? C Hartmann, B Hentschel, M Tatagiba, J Schramm, O Schnell, C Seidel, ... Clinical Cancer Research 17 (13), 4588-4599, 2011 | 219 | 2011 |
| A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma M Westphal, O Heese, JP Steinbach, O Schnell, G Schackert, M Mehdorn, ... European journal of cancer 51 (4), 522-532, 2015 | 213 | 2015 |
| Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The … U Herrlinger, N Schäfer, JP Steinbach, A Weyerbrock, P Hau, ... Journal of Clinical Oncology 34 (14), 1611-1619, 2016 | 197 | 2016 |
| Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma VM Ravi, P Will, J Kueckelhaus, N Sun, K Joseph, H Salié, L Vollmer, ... Cancer cell 40 (6), 639-655. e13, 2022 | 194 | 2022 |
